抗肿瘤血管新药的研究进展  

Progress on anti-angiogenesis new drugs

作　　者：陈 娇[1] 陈娇[1,2] 徐为人 

机构地区：[1]天津药物研究院天津市新药设计与发现重点实验室,天津300193 [2]天津医科大学,天津300070

出　　处：《现代药物与临床》2012年第1期1-5,共5页Drugs & Clinic

摘　　要：目前肿瘤血管靶向治疗新药的研究主要集中在两个方向,即肿瘤血管生成抑制剂(tumor angiogenesis inhibitor,TAI)和肿瘤血管靶向制剂(vascular targeting agent,VTA)。TAI类旨在抑制肿瘤血管生成的过程,近年来研究较多的为血管内皮生长因子(VEGF)类、基质金属蛋白酶(MMP)类、血管抑素类、内皮抑素类等;而VAT类则是通过破坏肿瘤组织中已存在的血管从而使肿瘤坏死,主要包括小分子类VTA和生物类VTA。对近年来各类抗肿瘤血管治疗新药的种类、作用机制及各自的临床研究进展进行综述。Nowadays two aspects were involved in research on new drugs of tumor vascular targeting therapy, including tumor angiogenesis inhibitor （TAI） and vascular targeting agent （VTA）. TAI aimed to inhibit the process of new angiogenesis and the most studied TAI agents were VEGF TAI, MMP TAI, angiostatin, endostatin and so on. The VTA induced a tumor necrosis through destroying vessels in tumor tissue, mainly including small molecularVTA and biological VTA. This review summarizes the types of anti-angiogenesis drug, their molecule mechanisms and the clinical research progress.

关 键 词：肿瘤血管生成抑制剂(TAI) 内皮生长因子(VEGF) 基质金属蛋白酶(MMP) 肿瘤血管靶向制剂(VTA) 

分 类 号：R979.1[医药卫生—药品]